Market Research Logo

North America and Europe PEGylated Drugs Market Size By Disease Indication (Cancer, Hepatitis, Multiple Sclerosis, Gastrointestinal Disorders), By Type (Monoclonal Antibodies, Colony Stimulating Factors, Interferons), Industry Analysis Report, Regional Ou

North America and Europe PEGylated Drugs Market Size By Disease Indication (Cancer, Hepatitis, Multiple Sclerosis, Gastrointestinal Disorders), By Type (Monoclonal Antibodies, Colony Stimulating Factors, Interferons), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Sweden), Application Potential, Price Trends, Competitive Market Share & Forecast, 2018 - 2024

North America & Europe PEGylated Drugs Market will reach USD 10.5 Billion by 2024; as per a new research report.

Rising incidences of chronic ailments including cancer, multiple sclerosis in the developed economies will act as a major driver for PEGylated drugs market growth. Favorable government support along with increasing funding for research and development by major biopharmaceutical companies in the U.S. and Europe will propel industry growth.

Growing biologics sector in the developed regions will substantially influence the PEGylated drugs industry over the coming few years. Growing investment for biologics, efficient regulatory process coupled with increased efforts of industry players to develop innovative medicines and drugs are factors contributing towards market growth.

Potential safety risks such as vacuolation and hypersensitivity reactions due to uptake of pegylated drugs will impede market growth. Drug recalls owing to adverse side effects of drugs is further expected to hamper revenue size.

Cancer dominated the industry owing to the high prevalence of the disease across North America and European region. Increasing government spending for cancer research along with availability of pegylated drugs such as Neulasta and Oncaspar offering numerous benefits for effective treatment of cancer will stimulate market growth in the future.

Multiple sclerosis will witness considerable growth over the coming years. This growth is attributable to increasing usage of Plegridy, a peginterferon beta-1 drug used for the treatment of relapsing multiple sclerosis.

Colony stimulating factors held the largest revenue share in 2017 due to increasing adoption of granulocyte CSF called pegfilgrastin. Benefits offered by such molecules such as reducing the risk of neutropenia and infections caused by bone marrow transplantation or chemotherapy will boost its market growth.

U.S. was dominating the PEGylated drugs industry due to the presence of large patient pool suffering from chronic disorders along with growing biologics sector in the country. Increasing investments for R&D by pharmaceutical players along with availability of numerous approved pegylated drugs will further contribute towards market growth.

Germany pegylated drugs market will experience considerable growth due to growing prevalence of chronic diseases along with presence of well-established and local players developing PEGylated drugs in the country.

Some of the notable industry players are Shire Group, UCB, Merck, AstraZeneca, Amgen, Sigma Tau, Biogen, Pfizer and Roche. Growing focus of major industry players on research activities for the development of effective therapeutics along with the presence of considerable number of products in their pipeline will escalate market growth in the coming years.


Report Content
Chapter 1. Methodology
1.1. Methodology
1.1.1. Methodology
1.1.2. Market definition
1.1.3. Forecast parameters
1.1.4. Data sources
1.1.4.1. Primary
1.1.4.2. Secondary
Chapter 2. Executive Summary
2.1. North America & Europe PEGylated drugs industry 360 degree synopsis, 2013 - 2024 (USD Million)
2.1.1. Business trends
2.1.2. Disease indication trends
2.1.3. Type trends
2.1.4. Regional trends
Chapter 3. North America & Europe PEGylated Drugs Industry Insights
3.1. Industry segmentation
3.2. Industry impact forces
3.2.1. Growth drivers
3.2.1.1. Increasing prevalence of cancer in developed regions
3.2.1.2. Rising R&D spending by biotechnology & pharmaceutical companies in U.S. and Europe
3.2.1.3. Growing biologics sector in the developed economies
3.2.2. Industry pitfalls & challenges
3.2.2.1. Drug recalls in the U.S. & Europe
3.2.2.2. Adverse drug reactions
3.3. Growth potential analysis
3.3.1. By disease indication
3.3.2. By type
3.4. Regulatory landscape
3.4.1. U.S.
3.4.2. Europe
3.5. Porter's analysis
3.6. Pipeline analysis
3.7. Competitive landscape, 2017
3.7.1. Strategy dashboard
3.8. PESTEL analysis
Chapter 4. North America & Europe PEGylated Drugs Market, By Disease Indication
4.1. North America & Europe PEGylated drugs market share by disease indication, 2017 & 2024
4.2. Cancer
4.2.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
4.3. Hepatitis
4.3.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
4.4. Multiple sclerosis
4.4.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
4.5. Gastrointestinal disorders
4.5.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
4.6. Others
4.6.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
Chapter 5. North America & Europe PEGylated Drugs, By Type
5.1. North America & Europe PEGylated drugs market share by type, 2017 & 2024
5.2. Monoclonal antibodies (mAbs)
5.2.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
5.3. Colony stimulating factors
5.3.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
5.4. Interferons
5.4.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
5.5. Others
5.5.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
Chapter 6. North America & Europe PEGylated Drugs Market, By Country
6.1. North America & Europe PEGylated drugs market share by country, 2017 & 2024
6.2. North America
6.2.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
6.2.2. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.2.3. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
6.2.4. U.S.
6.2.4.1. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.2.4.2. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
6.2.5. Canada
6.2.5.1. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.2.5.2. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
6.3. Europe
6.3.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
6.3.2. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.3.3. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
6.3.4. Germany
6.3.4.1. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.3.4.2. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
6.3.5. France
6.3.5.1. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.3.5.2. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
6.3.6. UK
6.3.6.1. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.3.6.2. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
6.3.7. Spain
6.3.7.1. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.3.7.2. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
Chapter 7. Company Profiles
7.1. Merck KGaA
7.1.1. Business overview
7.1.2. Financial data
7.1.3. Product landscape
7.1.4. Strategic outlook
7.1.5. SWOT analysis
7.2. Biogen Inc.
7.2.1. Business overview
7.2.2. Financial data
7.2.3. Product landscape
7.2.4. Strategic outlook
7.2.5. SWOT analysis
7.3. AstraZeneca
7.3.1. Business overview
7.3.2. Financial data
7.3.3. Product landscape
7.3.4. Strategic outlook
7.3.5. SWOT analysis
7.4. UCB
7.4.1. Business overview
7.4.2. Financial data
7.4.3. Product landscape
7.4.4. Strategic outlook
7.4.5. SWOT analysis
7.5. Amgen
7.5.1. Business overview
7.5.2. Financial data
7.5.3. Product landscape
7.5.4. Strategic outlook
7.5.5. SWOT analysis
7.6. Sigma Tau (Leadiant Biosciences)
7.6.1. Business overview
7.6.2. Financial data
7.6.3. Product landscape
7.6.4. Strategic outlook
7.6.5. SWOT analysis
7.7. Roche
7.7.1. Business overview
7.7.2. Financial data
7.7.3. Product landscape
7.7.4. Strategic outlook
7.7.5. SWOT analysis
7.8. Shire Group
7.8.1. Business overview
7.8.2. Financial data
7.8.3. Product landscape
7.8.4. Strategic outlook
7.8.5. SWOT analysis
7.9. Pfizer
7.9.1. Business overview
7.9.2. Financial data
7.9.3. Product landscape
7.9.4. Strategic outlook
7.9.5. SWOT analysis
7.10. Novo Nordisk
7.10.1. Business overview
7.10.2. Financial data
7.10.3. Product landscape
7.10.4. Strategic outlook
7.10.5. SWOT analysis
Data Tables
TABLE 1. North America & Europe PEGylated drugs industry 360 degree synopsis, 2013 - 2024
TABLE 2. Industry impact forces
TABLE 3. Cancer market size, by country, 2013 - 2024
TABLE 4. Hepatitis market size, by country, 2013 - 2024
TABLE 5. Multiple sclerosis market size, by country, 2013 - 2024
TABLE 6. Gastrointestinal disorders market size, by country, 2013 - 2024
TABLE 7. Others market size, by country, 2013 - 2024
TABLE 8. Monoclonal antibodies (mAbs) market size, by country, 2013 - 2024
TABLE 9. Colony stimulating factors market size, by country, 2013 - 2024
TABLE 10. Interferons market size, by country, 2013 - 2024
TABLE 11. Others market size, by country, 2013 - 2024
TABLE 12. North America PEGylated drugs market, by country 2013 - 2024
TABLE 13. North America PEGylated drugs market, by disease indication, 2013 - 2024
TABLE 14. North America PEGylated drugs market, by type, 2013 - 2024
TABLE 15. U.S PEGylated drugs market, by disease indication, 2013 - 2024
TABLE 16. U.S. PEGylated drugs market, by type, 2013 - 2024
TABLE 17. Canada PEGylated drugs market, by disease indication, 2013 - 2024
TABLE 18. Canada PEGylated drugs market, by type, 2013 - 2024
TABLE 19. Europe PEGylated drugs market, by country 2013 - 2024
TABLE 20. Europe PEGylated drugs market, by disease indication, 2013 - 2024
TABLE 21. Europe PEGylated drugs market, by type, 2013 - 2024
TABLE 22. Germany PEGylated drugs market, by disease indication, 2013 - 2024
TABLE 23. Germany PEGylated drugs market, by type, 2013 - 2024
TABLE 24. UK PEGylated drugs market, by disease indication, 2013 - 2024
TABLE 25. UK PEGylated drugs market, by type, 2013 - 2024
TABLE 26. France PEGylated drugs market, by disease indication, 2013 - 2024
TABLE 27. France PEGylated drugs market, by type, 2013 - 2024
TABLE 28. Spain PEGylated drugs market, by disease indication, 2013 - 2024
TABLE 29. Spain PEGylated drugs market, by type, 2013 - 2024
TABLE 30. Italy PEGylated drugs market, by disease indication, 2013 - 2024
TABLE 31. Italy PEGylated drugs market, by disease indication, 2013 - 2024
Charts & Figures
FIG. 1 Industry segmentation
FIG. 2 Growth potential analysis
FIG. 3 Porter's analysis
FIG. 4 PESTEL analysis
FIG. 5 Strategy dashboard
FIG. 6 North America & Europe PEGylated drugs market share, by disease indication, 2017 & 2024
FIG. 7 North America & Europe PEGylated drugs market share, by type, 2017 & 2024
FIG. 8 North America & Europe PEGylated drugs market share, by country, 2017 & 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report